AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-15. (Canceled).

16. (New) A method for the treatment of oligoasthenoteratospermia comprising administering to a patient in need thereof an effective amount of a combination of L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts, or of their pharmaceutically acceptable salts.

17. (New) The method according to claim 16, wherein oligospermia is treated.

18. (New) The method according to claim 16, wherein asthenospermia is treated.

19. (New) The method according to claim 16, wherein teratospermia is treated.

20. (New) The method according to claim 16 in which the pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartate, acid aspartate, citrate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate, acid fumarate, magnesium fumarate, glycerophosphate, lactate, maleate and acid maleate, mucate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate, acid tartrate, magnesium tartrate, 2-amino ethane sulphonate, magnesium 2-amino ethane sulphonate, methane sulphonate, choline tartrate, trichloroacetate and trifluoroacetate.

21. (New) The method according to claim 16, in which a molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.098:0.092 to 0.186:0.98:0.92.

22. (New) The method according to claim 16, in which a molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.49:0.46 to 0.62:0.49:0.46.

23. (New) The method according to claim 16, in which a molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.98:0.92 to 1.24:0.49:0.23.

24. (New) The method according to claim 16, in which the patient is administered a composition in unit dosage form which contains L-carnitine inner salt in amounts ranging from 4.0 g to 0.30 g, acetyl L-carnitine inner salt in amounts ranging from 0.20 to 2.0 g, and propionyl L-carnitine inner salt in amounts ranging from 0.20 g to 2.0 g, or equimolar amounts of their pharmaceutically acceptable salts.

25. (New) The method according to claim 24, in which the unit dosage form contains 2 g of L-carnitine inner salt, 1 g of acetyl L-carnitine inner salt and 0.5 g of propionyl L-carnitine inner salt or equimolar amounts of their pharmaceutically acceptable salts.

26. (New) A method for the treatment of oligoasthenoteratospermia comprising administering to a patient in need thereof an effective amount of a combination of L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts, or of their pharmaceutically acceptable salts wherein the pharmaceutically acceptable salt is not zinc citrate.

27. (New) The method according to claim 26 in which the pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartate, acid aspartate, citrate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate, acid fumarate, magnesium fumarate, glycerophosphate, lactate, maleate and acid maleate, mucate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate,

acid tartrate, magnesium tartrate, 2-amino ethane sulphonate, magnesium 2-amino ethane sulphonate, methane sulphonate, choline tartrate, trichloroacetate and trifluoroacetate.

28. (New) The method according to claim 26, wherein oligospermia is treated.

29. (New) The method according to claim 26, wherein asthenospermia is treated.

30. (New) The method according to claim 26, wherein teratospermia is treated.

31. (New) The method according to claim 26, in which a molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.098:0.092 to 0.186:0.98:0.92.

32. (New) The method according to claim 26, in which a molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.49:0.46 to 0.62:0.49:0.46.

33. (New) The method according to claim 26, in which a molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.98:0.92 to 1.24:0.49:0.23.

34. (New) The method according to claim 26, in which the patient is administered a composition in unit dosage form which contains L-carnitine inner salt in amounts ranging from 4.0 g to 0.30 g, acetyl L-carnitine inner salt in amounts ranging from 0.20 to 2.0 g, and propionyl L-carnitine inner salt in amounts ranging from 0.20 g to 2.0 g, or equimolar amounts of their pharmaceutically acceptable salts.

35. (New) The method according to claim 34, in which the unit dosage form contains 2 g of L-carnitine inner salt, 1 g of acetyl L-carnitine inner salt and 0.5 g of propionyl L-carnitine inner salt or equimolar amounts of their pharmaceutically acceptable salts.

36. (New) A method for the treatment of oligoasthenoteratospermia comprising administering to a patient in need thereof an effective amount of a combination of L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts, or of their pharmaceutically acceptable salts in which a molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.098:0.092 to 0.186:0.98:0.92.

37. (New) The method according to claim 36, wherein oligospermia is treated.

38. (New) The method according to claim 36, wherein asthenospermia is treated.

39. (New) The method according to claim 36, wherein teratospermia is treated.

40. (New) The method according to claim 36 in which the pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, orotate, aspartate, acid aspartate, citrate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate, acid fumarate, magnesium fumarate, glycerophosphate, lactate, maleate and acid maleate, mucate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate, acid tartrate, magnesium tartrate, 2-amino ethane sulphonate, magnesium 2-amino ethane sulphonate, methane sulphonate, choline tartrate, trichloroacetate and trifluoroacetate.

41. (New) The method according to claim 36, in which a molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.49:0.46 to 0.62:0.49:0.46.

42. (New) The method according to claim 36, in which a molar ratio of L-carnitine to acetyl L-carnitine and propionyl L-carnitine or of their pharmaceutically acceptable salts ranges from 2.48:0.98:0.92 to 1.24:0.49:0.23.

43. (New) The method according to claim 36, in which the patient is administered a composition in unit dosage form which contains L-carnitine inner salt in amounts ranging from 4.0 g to 0.30 g, acetyl L-carnitine inner salt in amounts ranging from 0.20 to 2.0 g, and propionyl L-carnitine inner salt in amounts ranging from 0.20 g to 2.0 g, or equimolar amounts of their pharmaceutically acceptable salts.

44. (New) The method according to claim 43, in which the unit dosage form contains 2 g of L-carnitine inner salt, 1 g of acetyl L-carnitine inner salt and 0.5 g of propionyl L-carnitine inner salt or equimolar amounts of their pharmaceutically acceptable salts.